Features

The 2015 Annual meeting of the American Association of Pharmaceutical Scientists took place October 25-29 at the Orange County Convention Center in Orlando, FL. Attendance numbers for the meeting were not released, but the exposition… Read more . . .

Approximately 450 OINDP experts gathered May 5-8 in Antibes, France for the 10th anniversary iteration of RDD Europe, which featured scientific presentations and posters, a series of workshops, a technical exhibition, and numerous networking opportunities.… Read more . . .

Optimizing a dry powder inhaler (DPI) to achieve the desired emitted dose and aerodynamic particle size distribution (APSD) can be made significantly faster and easier by using data acquired by laser diffraction and morphologically directed… Read more . . .

Since 2000, developers of immediate-release oral drugs have been able to request waivers of in vivo bioequivalence studies based on the FDA’s Biopharmaceutics Classification System (BCS). Now a workshop sponsored by the AAPS Inhalation and… Read more . . .

DDL 25 conference chair Gary Pitcairn opened the Silver Anniversary edition of Drug Delivery to the Lungs by welcoming approximately 550 attendees to the Edinburgh International Conference Centre. With the meeting’s rapid growth in attendance… Read more . . .

Twenty-five years after its first meeting in a Glaxo Group Research lecture theater, the Aerosol Society’s annual Drug Delivery to the Lungs conference marks its silver anniversary with DDL 25, taking place December 10-12 at… Read more . . .

Recent product-specific pharmacopeial monographs intended to assist developers of inhaled generic drugs call for the use of test equipment not specified in the USP/Ph. Eur. chapters on orally inhaled products. In this Q&A, Copley Scientific… Read more . . .

At the recent Orlando Inhalation Conference, Bing Li of the FDA’s Division of Bioequivalence in the Office of Generic Drugs of the Center for Drug Evaluation and Research (CDER) offered practical advice for companies submitting… Read more . . .